title: Efficacy and toxicity of a rituximab and methotrexate based regimen (GMALL B-ALL/NHL 2002 protocol) in Burkitt's and primary mediastinal large B-cell lymphoma.
abstract: There have been several attempts to improve treatment and outcome of patients with primary mediastinal B-cell lymphoma (PMBL) and Burkitt's lymphoma (BL). In recent years, chemotherapy dose intensification and the addition of rituximab have led to a remarkable progress and have developed into integral parts of treatment for both entities of lymphoma [1–4]. Here, we report our monocenter results of a high-dose methotrexate based alternating regimen with rituximab (B-ALL/NHL 2002 protocol) in 15 patients with PMBL and 28 patients with sporadic BL. Since the early 1980s, protocols of GMALL have been continuously adapted and in the meantime they have become reference treatment for BL and B-ALL in Germany. The latest changes comprised the additional use of rituximab, standardized G-CSF support,implementation of high-dose cytarabine, intrathecal triple therapy,and age-adjusted stratification. Furthermore, we additionally amended supportive care with palifermin as it reduced severity and prevalence of mucositis [5].
authors: Department of Medicine A, Hematology/Oncology, University Hospital Muenster, Muenster, Germany. michele.pohlen@ukmuenster.de
authors: Michele
authors: M
authors: Pohlen
authors: Hans U
authors: HU
authors: Gerth
authors: Ruediger
authors: R
authors: Liersch
authors: Steffen
authors: S
authors: Koschmieder
authors: Rolf M
authors: RM
authors: Mesters
authors: Torsten
authors: T
authors: Kessler
authors: Iris
authors: I
authors: Appelmann
authors: Carsten
authors: C
authors: Müller-Tidow
authors: Wolfgang E
authors: WE
authors: Berdel
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy* / Q000473:pathology; D015331:Cohort Studies; D005260:Female; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use; D006801:Humans; D016393:Lymphoma, B-Cell / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008479:Mediastinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D052016:Mucositis / Q000139:chemically induced / Q000517:prevention & control; D009367:Neoplasm Staging; D000069283:Rituximab; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D051523:Fibroblast Growth Factor 7; D000069283:Rituximab; D008727:Methotrexate